Haleon plc(HLN)Earnings, Financials & Key Ratios
HLN•NYSE
$9.23
$41.1B mkt cap·18.9× P/E·Price updated May 6, 2026
AboutHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.Show more
- Revenue$10.79B-4.0%
- EBITDA$2.77B+15.4%
- Net Income$1.63B+13.1%
- EPS (Diluted)0.36+12.5%
- Gross Margin64.77%+4.7%
- EBITDA Margin25.7%+20.2%
- Operating Margin22.44%+14.3%
- Net Margin15.11%+17.7%
- ROE9.98%+14.0%
- ROIC7.59%+13.0%
- Debt/Equity0.52-16.1%
- Interest Coverage7.28+30.0%
HLN Key Insights
Haleon plc (HLN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 18.3% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 12.3%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HLN Price & Volume
Haleon plc (HLN) stock price & volume — 10-year historical chart
Loading chart...
HLN Growth Metrics
Haleon plc (HLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years1.75%
3 Years-0.21%
TTM10.69%
Profit CAGR
10 Years-
5 Years7.33%
3 Years15.43%
TTM50.17%
EPS CAGR
10 Years-
5 Years8.45%
3 Years14.47%
TTM53.28%
Return on Capital
10 Years6.06%
5 Years6.87%
3 Years7.64%
Last Year8.62%
HLN Recent Earnings
Haleon plc (HLN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 6/12 qtrs (60%)
Q1 2026Latest
Feb 25, 2026EPS
$0.26
Est $0.25
+3.4%
Revenue
$7.5B
Est $7.6B
-0.8%
Q4 2025
Oct 30, 2025EPS
$0.14
Est $0.24
-42.8%
Revenue
$7.5B
Est $2.8B
+171.9%
Q3 2025
Aug 7, 2025EPS
$0.08
Est $0.24
-67.3%
Revenue
$7.3B
Est $2.8B
+162.4%
Q1 2025
Feb 27, 2025EPS
$0.05
Est $25.25
-99.8%
Revenue
$7.1B
Est $2.7B
+161.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.26vs $0.25+3.4% | $7.5Bvs $7.6B-0.8% |
| Q4 2025 | Oct 30, 2025 | $0.14vs $0.24-42.8% | $7.5Bvs $2.8B+171.9% |
| Q3 2025 | Aug 7, 2025 | $0.08vs $0.24-67.3% | $7.3Bvs $2.8B+162.4% |
| Q1 2025 | Feb 27, 2025 | $0.05vs $25.25-99.8% | $7.1Bvs $2.7B+161.2% |
Based on last 12 quarters of dataView full earnings history →
HLN Peer Comparison
Haleon plc (HLN) competitors in Consumer health and OTC self-care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KVUE | 33.87B | 17.68 | 32.74 | 0.07% | 9.55% | 13.48% | 0.90 | |
 CHD | 22.49B | 94.96 | 31.44 | 1.57% | 11.81% | 17.45% | 0.55 | |
 PG | 345.67B | 147.93 | 22.72 | 0.29% | 14.66% | 23.78% | 0.68 | |
 CL | 70.73B | 88.16 | 33.52 | 1.4% | 10.46% | 251.59% | 21.88 | |
 PBH | 2.57B | 54.31 | 12.66 | 1.1% | 16.9% | 10.19% | 0.57 | |
 JNJ | 541.31B | 224.62 | 38.79 | 4.3% | 27.26% | 31.69% | 0.51 | |
 NVS | 283.08B | 148.36 | 20.63 | 5.97% | 24.14% | 31.42% | 0.80 | |
 GSK | 101.62B | 50.53 | 6.69 | 4.11% | 19.19% | 31.48% | 1.11 |
Compare HLN vs Peers
Haleon plc (HLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HLN Income Statement
Haleon plc (HLN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.48B | 9.89B | 9.54B | 10.86B | 11.3B | 11.23B | 10.79B |
| Revenue Growth % | - | 16.65% | -3.51% | 13.76% | 4.09% | -0.61% | -3.96% |
| Cost of Goods Sold | 3.68B | 3.98B | 3.6B | 4.28B | 4.34B | 4.29B | 3.8B |
| COGS % of Revenue | 43.37% | 40.25% | 37.66% | 39.43% | 38.41% | 38.15% | 35.23% |
| Gross Profit | 4.8B▲ 0% | 5.91B▲ 23.1% | 5.95B▲ 0.7% | 6.58B▲ 10.5% | 6.96B▲ 5.8% | 6.95B▼ 0.2% | 6.99B▲ 0.6% |
| Gross Margin % | 56.63% | 59.75% | 62.34% | 60.57% | 61.59% | 61.85% | 64.77% |
| Gross Profit Growth % | - | 23.07% | 0.68% | 10.54% | 5.84% | -0.19% | 0.57% |
| Operating Expenses | 3.9B | 4.31B | 4.31B | 4.75B | 4.96B | 4.74B | 4.57B |
| OpEx % of Revenue | 46.05% | 43.59% | 45.18% | 43.77% | 43.93% | 42.21% | 42.33% |
| Selling, General & Admin | 3.6B | 4.22B | 3.79B | 4.04B | 4.29B | 4.33B | 4.26B |
| SG&A % of Revenue | 42.41% | 42.66% | 39.74% | 37.18% | 37.94% | 38.57% | 39.47% |
| Research & Development | 292M | 304M | 257M | 300M | 311M | 298M | 308.1M |
| R&D % of Revenue | 3.44% | 3.07% | 2.69% | 2.76% | 2.75% | 2.65% | 2.86% |
| Other Operating Expenses | 17M | -212M | 262M | 415M | 366M | 111M | 0 |
| Operating Income | 897M▲ 0% | 1.6B▲ 78.1% | 1.64B▲ 2.5% | 1.82B▲ 11.4% | 2B▲ 9.4% | 2.21B▲ 10.5% | 2.42B▲ 9.7% |
| Operating Margin % | 10.58% | 16.15% | 17.16% | 16.81% | 17.66% | 19.64% | 22.44% |
| Operating Income Growth % | - | 78.15% | 2.5% | 11.42% | 9.37% | 10.52% | 9.74% |
| EBITDA | 1.16B | 1.9B | 1.91B | 2.11B | 2.31B | 2.4B | 2.77B |
| EBITDA Margin % | 13.64% | 19.24% | 19.97% | 19.45% | 20.39% | 21.38% | 25.7% |
| EBITDA Growth % | - | 64.48% | 0.16% | 10.81% | 9.14% | 4.21% | 15.44% |
| D&A (Non-Cash Add-back) | 260M | 305M | 268M | 287M | 309M | 196M | 352.11M |
| EBIT | 912M | 1.61B | 1.94B | 1.9B | 2.04B | 2.32B | 2.42B |
| Net Interest Income | -2.55M | -7.69M | -3M | -278.38M | -400M | -339M | -256.26M |
| Interest Income | 25.51M | 17.95M | 13M | 68.98M | 14M | 55M | 76.29M |
| Interest Expense | 28.07M | 25.65M | 16M | 347.36M | 414M | 394M | 332.55M |
| Other Income/Expense | -11M | -7M | -2M | -207M | -368M | -296M | -315.92M |
| Pretax Income | 886M▲ 0% | 1.59B▲ 79.6% | 1.64B▲ 2.8% | 1.62B▼ 1.1% | 1.63B▲ 0.6% | 1.91B▲ 17.3% | 2.1B▲ 10.2% |
| Pretax Margin % | 10.45% | 16.08% | 17.14% | 14.9% | 14.4% | 17% | 19.51% |
| Income Tax | 199M | 410M | 197M | 499M | 517M | 435M | 461.66M |
| Effective Tax Rate % | 22.46% | 25.77% | 12.04% | 30.84% | 31.76% | 22.77% | 21.93% |
| Net Income | 655M▲ 0% | 1.15B▲ 74.8% | 1.39B▲ 21.4% | 1.06B▼ 23.7% | 1.05B▼ 1.0% | 1.44B▲ 37.5% | 1.63B▲ 13.1% |
| Net Margin % | 7.72% | 11.58% | 14.56% | 9.76% | 9.28% | 12.84% | 15.11% |
| Net Income Growth % | - | 74.81% | 21.4% | -23.74% | -1.04% | 37.46% | 13.07% |
| Net Income (Continuing) | 687M | 1.18B | 1.44B | 1.12B | 1.11B | 1.48B | 1.64B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 91M | 111M | 125M | 126M | 123M | 58M | 58.9M |
| EPS (Diluted) | 0.14▲ 0% | 0.24▲ 71.4% | 0.30▲ 25.0% | 0.24▼ 20.0% | 0.24▲ 0.0% | 0.32▲ 33.3% | 0.36▲ 12.5% |
| EPS Growth % | - | 71.43% | 25% | -20% | 0% | 33.33% | 12.5% |
| EPS (Basic) | 0.14 | 0.24 | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
| Diluted Shares Outstanding | 4.62B | 4.62B | 4.62B | 4.62B | 4.63B | 4.59B | 4.51B |
| Basic Shares Outstanding | 4.62B | 4.62B | 4.62B | 4.62B | 4.63B | 4.57B | 4.48B |
| Dividend Payout Ratio | 175.88% | 207.07% | 82.59% | 253.02% | 36.99% | 39.53% | 36.71% |
HLN Balance Sheet
Haleon plc (HLN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.81B | 5.01B | 5.25B | 4.06B | 4.82B | 5.72B | 4.54B |
| Cash & Short-Term Investments | 340M | 334M | 414M | 684M | 1.04B | 2.25B | 1.32B |
| Cash Only | 340M | 334M | 414M | 684M | 1.04B | 2.19B | 1.32B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 55M | 0 |
| Accounts Receivable | 3.99B | 1.35B | 3.83B | 1.49B | 1.35B | 1.9B | 2.12B |
| Days Sales Outstanding | 171.91 | 49.74 | 146.27 | 49.99 | 43.66 | 61.87 | 71.7 |
| Inventory | 1.21B | 949M | 951M | 1.35B | 1.41B | 1.19B | 1.02B |
| Days Inventory Outstanding | 120.18 | 86.99 | 96.55 | 114.93 | 118.39 | 101.37 | 98.26 |
| Other Current Assets | 237M | 2.32B | 5M | 434M | 907M | 223M | 77.86M |
| Total Non-Current Assets | 29.9B | 29.12B | 29.2B | 30.76B | 29.24B | 28.6B | 28.03B |
| Property, Plant & Equipment | 1.62B | 1.6B | 1.66B | 1.9B | 1.9B | 1.92B | 1.99B |
| Fixed Asset Turnover | 5.23x | 6.17x | 5.74x | 5.72x | 5.94x | 5.85x | 5.41x |
| Goodwill | 8.17B | 8.27B | 8.25B | 8.4B | 8.32B | 8.2B | 0 |
| Intangible Assets | 19.84B | 18.95B | 18.95B | 20.04B | 18.54B | 18.01B | 0 |
| Long-Term Investments | 3M | 0 | 23M | 44M | 65M | 82M | 75.87M |
| Other Non-Current Assets | 10M | 51M | 8M | 157M | 415M | 383M | 104.82M |
| Total Assets | 35.71B▲ 0% | 34.13B▼ 4.4% | 34.45B▲ 0.9% | 34.81B▲ 1.1% | 34.05B▼ 2.2% | 34.31B▲ 0.8% | 32.57B▼ 5.1% |
| Asset Turnover | 0.24x | 0.29x | 0.28x | 0.31x | 0.33x | 0.33x | 0.33x |
| Asset Growth % | - | -4.43% | 0.94% | 1.06% | -2.18% | 0.76% | -5.08% |
| Total Current Liabilities | 4.27B | 4.01B | 4.24B | 4.37B | 4.64B | 5.81B | 4.92B |
| Accounts Payable | 1.9B | 1.83B | 1.58B | 1.83B | 1.85B | 1.97B | 3.72B |
| Days Payables Outstanding | 188.36 | 167.47 | 160.32 | 156.45 | 155.97 | 168.06 | 357.57 |
| Short-Term Debt | 481M | 348M | 874M | 393M | 608M | 1.44B | 834.53M |
| Deferred Revenue (Current) | 7M | 11M | 11M | 23M | 0 | 0 | 0 |
| Other Current Liabilities | 913M | 958M | 1.43B | 1.61B | 1.57B | 693M | 99.82M |
| Current Ratio | 1.36x | 1.25x | 1.24x | 0.93x | 1.04x | 0.98x | 0.92x |
| Quick Ratio | 1.08x | 1.01x | 1.01x | 0.62x | 0.73x | 0.78x | 0.71x |
| Cash Conversion Cycle | 103.73 | -30.74 | 82.51 | 8.46 | 6.08 | -4.83 | -187.61 |
| Total Non-Current Liabilities | 4.03B | 3.89B | 3.73B | 13.99B | 12.69B | 12.28B | 11.19B |
| Long-Term Debt | 0 | 0 | 0 | 9.89B | 8.71B | 8.54B | 7.76B |
| Capital Lease Obligations | 121M | 105M | 87M | 117M | 89M | 73M | 0 |
| Deferred Tax Liabilities | 3.51B | 0 | 3.36B | 3.6B | 3.49B | 3.35B | 3.22B |
| Other Non-Current Liabilities | 0 | 3.79B | 0 | 384M | 424M | 311M | 217.62M |
| Total Liabilities | 8.3B | 7.91B | 7.97B | 18.36B | 17.33B | 18.09B | 16.12B |
| Total Debt | 642M | 487M | 991M | 10.44B | 9.46B | 10.1B | 8.59B |
| Net Debt | 302M | 153M | 577M | 9.76B | 8.41B | 7.91B | 7.27B |
| Debt / Equity | 0.02x | 0.02x | 0.04x | 0.63x | 0.57x | 0.62x | 0.52x |
| Debt / EBITDA | 0.55x | 0.26x | 0.52x | 4.94x | 4.10x | 4.21x | 3.10x |
| Net Debt / EBITDA | 0.26x | 0.08x | 0.30x | 4.62x | 3.65x | 3.29x | 2.62x |
| Interest Coverage | 31.96x | 62.31x | 102.38x | 5.25x | 4.82x | 5.60x | 7.28x |
| Total Equity | 27.41B▲ 0% | 26.22B▼ 4.3% | 26.48B▲ 1.0% | 16.46B▼ 37.9% | 16.73B▲ 1.7% | 16.22B▼ 3.0% | 16.46B▲ 1.4% |
| Equity Growth % | - | -4.34% | 0.98% | -37.85% | 1.65% | -3.02% | 1.42% |
| Book Value per Share | 5.94 | 5.68 | 5.73 | 3.56 | 3.61 | 3.54 | 3.65 |
| Total Shareholders' Equity | 27.32B | 26.11B | 26.36B | 16.33B | 16.61B | 16.17B | 16.4B |
| Common Stock | 1M | 1M | 1M | 92M | 92M | 91M | 89.84M |
| Retained Earnings | 5.11B | 37.76B | 37.99B | 26.73B | 27.47B | 27.27B | 27.8B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -116M | 0 |
| Accumulated OCI | 1.37B | -11.65B | -11.63B | 1.2B | -10.96B | 0 | 0 |
| Minority Interest | 91M | 111M | 125M | 126M | 123M | 58M | 58.9M |
HLN Cash Flow Statement
Haleon plc (HLN) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 786M | 1.41B | 1.36B | 2.06B | 2.1B | 2.3B | 2.29B |
| Operating CF Margin % | 9.27% | 14.22% | 14.21% | 19% | 18.58% | 20.48% | 21.19% |
| Operating CF Growth % | - | 79.01% | -3.62% | 52.14% | 1.79% | 9.57% | -0.66% |
| Net Income | 687M | 1.18B | 1.39B | 1.12B | 1.3B | 1.44B | 1.63B |
| Depreciation & Amortization | 260M | 305M | 268M | 287M | 309M | 324M | 352.11M |
| Stock-Based Compensation | 58M | 63M | 59M | 78M | 88M | 102M | 0 |
| Deferred Taxes | 199M | 0 | 197M | 62M | 0 | 0 | 0 |
| Other Non-Cash Items | 43M | -157M | -406M | 336M | 506.04M | 385M | 52.82M |
| Working Capital Changes | -461M | 15M | -152M | 181M | -107M | 48M | 250.39M |
| Change in Receivables | -57M | 18M | 14M | -85M | 38M | -312M | -63.58M |
| Change in Inventory | 232M | 130M | -17M | -292M | -131M | 216M | 130.09M |
| Change in Payables | -256M | 140M | 41M | 387M | 112M | 0 | 122.26M |
| Cash from Investing | 291M | 1.03B | -33M | -8.78B | -134M | 528M | -567.29M |
| Capital Expenditures | -243M | -318M | -298M | -328M | -234M | -250M | -403.95M |
| CapEx % of Revenue | 2.87% | 3.21% | 3.12% | 3.02% | 2.07% | 2.23% | 3.74% |
| Acquisitions | 120M | 241M | 112M | 9.21B | -71M | 0 | -157.47M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 142M | 853M | 165M | -9.16B | 171M | 778M | 0 |
| Cash from Financing | -925M | -2.44B | -1.24B | 6.91B | -1.57B | -1.54B | -2.55B |
| Debt Issued (Net) | 1M | 28M | 8M | 9.49B | -553M | 592M | -1.28B |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | -1000K | -1000K | -1000K |
| Dividends Paid | -1.15B | -2.37B | -1.15B | -2.68B | -388M | -570M | -598.59M |
| Share Repurchases | 0 | 0 | 0 | 0 | -38M | -121M | -639.67M |
| Other Financing | 226M | -94M | -96M | 107M | -589M | -1.44B | -39.12M |
| Net Change in Cash | 138M▲ 0% | -6M▼ 104.3% | 82M▲ 1466.7% | 205M▲ 150.0% | 383M▲ 86.8% | 1.21B▲ 216.7% | -769.66M▼ 163.5% |
| Free Cash Flow | 543M▲ 0% | 1.09B▲ 100.6% | 1.06B▼ 2.8% | 1.74B▲ 64.0% | 1.76B▲ 1.7% | 2.05B▲ 16.3% | 1.97B▼ 3.9% |
| FCF Margin % | 6.4% | 11.01% | 11.08% | 15.98% | 15.61% | 18.26% | 18.27% |
| FCF Growth % | - | 100.55% | -2.85% | 63.99% | 1.67% | 16.27% | -3.91% |
| FCF per Share | 0.12 | 0.24 | 0.23 | 0.38 | 0.38 | 0.45 | 0.44 |
| FCF Conversion (FCF/Net Income) | 1.20x | 1.23x | 0.98x | 1.95x | 2.00x | 1.60x | 1.40x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 360M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HLN Key Ratios
Haleon plc (HLN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 2.39% | 4.27% | 5.27% | 4.94% | 6.32% | 8.75% | 9.98% |
| Return on Invested Capital (ROIC) | 2.43% | 4.43% | 4.6% | 5.14% | 5.83% | 6.72% | 7.59% |
| Gross Margin | 56.63% | 59.75% | 62.34% | 60.57% | 61.59% | 61.85% | 64.77% |
| Net Margin | 7.72% | 11.58% | 14.56% | 9.76% | 9.28% | 12.84% | 15.11% |
| Debt / Equity | 0.02x | 0.02x | 0.04x | 0.63x | 0.57x | 0.62x | 0.52x |
| Interest Coverage | 31.96x | 62.31x | 102.38x | 5.25x | 4.82x | 5.60x | 7.28x |
| FCF Conversion | 1.20x | 1.23x | 0.98x | 1.95x | 2.00x | 1.60x | 1.40x |
| Revenue Growth | - | 16.65% | -3.51% | 13.76% | 4.09% | -0.61% | -3.96% |
HLN Frequently Asked Questions
Haleon plc (HLN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Haleon plc (HLN) reported $22.01B in revenue for fiscal year 2025. This represents a 160% increase from $8.48B in 2019.
Haleon plc (HLN) saw revenue decline by 4.0% over the past year.
Yes, Haleon plc (HLN) is profitable, generating $3.18B in net income for fiscal year 2025 (15.1% net margin).
Dividend & Returns
Yes, Haleon plc (HLN) pays a dividend with a yield of 1.96%. This makes it attractive for income-focused investors.
Haleon plc (HLN) has a return on equity (ROE) of 10.0%. This is below average, suggesting room for improvement.
Haleon plc (HLN) generated $3.12B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More HLN
Haleon plc (HLN) financial analysis — history, returns, DCA and operating performance tools
Full HLN Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates